Introduction
Since the last special review of cholesterol 7α-hydroxylase (CYP7A1) published in the Journal of Lipid Research in 1977 (1), there has been remarkable progress on the molecular mechanisms of regulation of bile acid synthesis. The cloning of the key regulatory gene CYP7A1 about twenty years ago (2-4), followed by the identification of the bile acid-activated receptor FXR (NR1H4) ten years later (5-7), has generated high interest in bile acid research. New functions of bile acids in metabolic regulation have been unraveled. It is now well recognized that bile acids are important signaling molecules that coordinately regulate a network of metabolic pathways including lipid, glucose, drug, and energy metabolism [Review in (8) (9) (10) (11) (12) (13) (14) (15) ].
The enterohepatic circulation of bile acids serves as an important physiological route not only for recycling of bile acids and absorption of nutrients but also for regulation of whole body lipid metabolism. However, the mechanism underlying this remarkably efficient and complex physiological process has only recently been unraveled. This review will provide an update on the current understanding of the molecular mechanism of regulation of bile acid synthesis, with a focus on the most critical regulatory gene in the pathway, CYP7A1.
It should be emphasized that the bile acid pool in mice consists mostly of hydrophilic bile acids, muricholic acids and cholic acid, and is very different from the hydrophobic bile acid pool consisting predominantly chenodeoxycholic acid (CDCA), cholic acid (CA) and deoxycholic acid (DCA) in humans. Hydrophobic, but not that play critical roles in the regulation of bile acid synthesis and metabolism. Therefore, results from studying bile acid synthesis in the mouse models may not be extrapolated to humans without verification in suitable human models. This review will focus on the regulation of bile acid synthesis in human livers and will address the species differences in regulation.
BILE ACIDS ARE VERSATILE SIGNALING MOLECULES
Bile acids are derived from cholesterol. Bile acid synthesis is the predominant metabolic pathway for catabolism of cholesterol in humans. Hydroxylation and modification of cholesterol to bile acids converts a hydrophobic membrane constituent to amphipathic molecules that can serve as powerful physiological detergents for absorption and transport of nutrients, fats and vitamins, but also as the versatile signaling molecules that are specific ligands for activation of nuclear and membrane receptors. Both free and conjugated-bile acids bind to the ligand-binding domain of FXR, which forms a heterodimer with retinoid X receptor (RXR) and binds to the inverted repeat of 6
The liver is the only organ that has all 14 enzymes required for de novo synthesis of two primary bile acids in humans, cholic acid (CA, 3α, 7α, 12α-trihydroxy-cholanoic acid) and chenodeoxycholic acid (CDCA, 3α, 7α-dihydroxy-cholanoic acid) (Fig 1) (40) .
The classic bile acid biosynthetic pathway is initiated by CYP7A1 (41) . Sterol 12α-hydroxylase (CYP8B1) is required for synthesis of CA. Mitochondrial sterol 27-hydroxylase (CYP27A1) catalyzes sterol side chain oxidation, after which cleavage of a three-carbon unit in the peroxisomes leads to formation of a C24 bile acid. An alternative (acidic) pathway is initiated by CYP27A1, which in addition to the liver is expressed in macrophages and most other tissues, and may contribute significantly to total bile acid synthesis. Other minor pathways initiated by 25-hydroxylase in the liver and 24-hydroxylase in the brain also may contribute to bile acid synthesis. A non-specific 7α-hydroxylase (CYP7B1) expressed in all tissues is involved in the generation of oxidized metabolites (oxysterols), which may be transported to the liver and converted to CDCA.
Most bile acids are conjugated to glycine or taurine to decrease toxicity and increase solubility for secretion into bile. Bile acid: CoA synthase (BACS) and bile acid: amino acid transferase (BAT) are involved in amino acid conjugation of bile acids. In the intestine, Glyco-and tauro-conjugated CA and CDCA are de-conjugated and 7α-dehydroxylase activity in bacteria flora removes a 7α-hydroxy group to form secondary bile acids, deoxycholic acid (DCA, 3α, 12-dihydroxy) and lithocholic acid (LCA, 3α-monohydroxy), respectively. CA, CDCA and DCA are reabsorbed in the intestine and transported back to the liver to inhibit bile acid synthesis. Most of the LCA is excreted in feces. Small amount of LCA circulated to the liver is sulfo-conjugated at the 3-hydroxyposition by sulfotransferase (SULT2A1) and rapidly secreted into bile. Sulfation is the by guest, on October 30, 2017 www.jlr.org Downloaded from major pathway for detoxification of extremely hydrophobic bile acids in humans (42) .
Details of bile acid chemistry, biology, physiology, and synthesis have been reviewed recently (43, 44) .
Regulation of the rate-limiting enzyme in bile acid biosynthetic pathways CYP7A1 has been studied extensively. The CYP7A1 mRNA transcripts in the 3'-untranslated region (3'-UTR) are unusually long (3), and have a very short half-life of about 30 min (45, 46) . It has been reported that bile acids reduce CYP7A1 mRNA stability via the bile acid response elements located in the 3'-untranslated region (3'-UTR) (46, 47) . Numerous studies have demonstrated that bile acids, steroid hormones, inflammatory cytokines, insulin and growth factors inhibit CYP7A1 transcription through the 5'-upstream region of the promoter (48) (49) (50) (51) (52) (53) .
Analysis of the proximal promoter of the rat Cyp7a1 identified two regions (footprints) that are putative binding sites for nuclear receptors (54) , which are ligandactivated transcription factors that play important roles in embryogenesis, development, and metabolism (18) . The sequence located at -73 to -55 of the rat CYP7A1 promoter is highly conserved and was identified as a putative bile acid response element (BARE-I) that might be involved in conferring bile acid inhibition. This sequence contains a DR4 (direct repeat spaced by 4 nucleotides) motif in all species except the human, which binds liver X receptor (LXRα or NR1H3), an oxysterol-activated nuclear receptor. The CYP7A1 is the first LXRα target gene identified (55, 56) . This has been confirmed by the finding that when fed a high cholesterol diet, bile acid synthesis increases in wild type mice, but not in Lxrα null mice, which accumulate high levels of cholesterol in the liver (57) . In contrast, the human CYP7A1 promoter does not bind LXRα and is not induced by LXRα due to alteration of the DR4 motif in the BARE-I sequence (58) . This has been confirmed by the finding that transgenic mice carrying a human CYP7A1 do not respond to a high cholesterol diet and that the transgene is not induced and bile acid synthesis is not stimulated in these mice (59, 60) . Another bile acid response element (BARE-II) is located in a region from -149 to -118 of the rat Cyp7a1 promoter, which has a 18-nucleotide sequence that is completely conserved in many species (61) . This sequence contains a DR1 motif, which binds hepatocyte nuclear factor 4α (HNF4α, NR2A1).
HNF4α trans-activates CYP7A1 promoter activity by interacting with a co-activator, peroxisome proliferator-activated receptor γ co-activator 1α (PGC-1α). Mutation of the DR1 sequence drastically reduced basal CYP7A1 promoter activity and its response to bile acid inhibition (48) .
Several earlier studies report that bile acid pool size increases in diabetic rats and insulin inhibits CYP7A1 and CYP8B1 activities [Review in (41) ]. Recent studies show that insulin-regulated transcription factor FoxO1 binds to an insulin response sequence in the rat Cyp7a1 promoter and induces rat Cyp7a1 transcription (50) . Insulin signaling phosphorylates FoxO1, which is excluded from the nucleus, and results in inhibiting rat CYP7A1. However, the FoxO1 binding site is not present in the human CYP7A1 promoter and FoxO1 functions as a repressor that inhibits HNF4α and PGC-1α activation of the human CYP7A1 (50) . In this study, insulin at the physiological concentrations rapidly stimulates CYP7A1 expression by inhibiting FoxO1, while high concentrations of insulin found in the insulin resistance state activate steroid response element binding protein-1c (SREBP-1c), which inhibits CYP7A1 expression by interacting with HNF4α.
On the other hand, glucagon and cAMP strongly inhibit CYP7A1 expression via activation of PKA, which phosphorylates HNF4α and abolishes HNF4α DNA-binding activity, and resulting in inhibition of CYP7A1 expression in human hepatocytes (51) . This is in contrast to other studies in mice that cAMP and fasting induces Cyp7a1 expression, which parallels the induction of PGC-1α and phosphoenolpyruvate carboxykinase (PEPCK) (62, 63) . These investigators suggest that Cyp7a1 expression and bile acid synthesis is up regulated during fasting and there is a coordinated regulation of bile acid synthesis and gluconeogenesis by the fasting-to-fed cycle. Biosynthetic pathways should be inactivated during fasting to conserve energy, except glucogeneogenesis, which provides energy during starvation. The induction of Cyp7a1 in fasting response in mice is in contrast to the observation in human patients that the serum 7α-hydroxy-4-cholesten-3-one (C4), a serum marker for bile acid synthesis and CYP7A1 enzyme activity, is reduced during the fasting, and increased during the postprandial state, and gradually decreased during the post-absorptive state (64) . In addition, bile acid synthesis increases in the morning regardless of food intakes (65) .
FXR plays a critical role in the regulation of bile acid synthesis and homeostasis (66) . However, FXR inhibits CYP7A1 (67), CYP8B1 (68) and CYP27A1 (69) transcription by complicated mechanisms described later. A recent study identified an FXR-binding site in the human but not mouse CYP8B1 promoter suggesting a speciesspecific regulation of bile acid synthesis by FXR (70) . A transcriptional repressor GPS2 differentially regulates CYP7A1 and CYP8B1 transcription by interacting with SHP, liver related homologue-1 (LRH-1, or human α-fetoprotein transcription factor, FTF, NR5A2), FXR, and HNF4α bound to these two promoters. In the CYP7A1 and CYP8B1 promoters, PPARα also regulates CYP27A1 expression in macrophages (75) . Activation of PPARα has been shown to increase un-conjugated bile acids by induction of peroxisomal bile acid thioesterase (76) , indicating that PPARα may play a role in balancing the amount of conjugated and free bile acids.
Orphan nuclear receptor Rev-erbα plays a role in the regulation of bile acid synthesis (77) . Rev-ERbα is a clock gene involved in the control of circadian rhythmicity (78) (79) (80) . The activity of Rev-erbα is activated by heme (81) and functions as a heme sensor and transcriptional repressor that regulates lipid metabolism and adipogenesis (82, 83) . Rev-erbα may coordinate energy metabolism and circadian rhythm during feeding and starvation (84) . It has been well documented that CYP7A1 and CYP8B1 expression exhibits a pronounced diurnal rhythm in both 12 hr light: 12 hr dark cycle and constant darkness (85-88). In humans bile acid synthesis exhibits a diurnal rhythm with two peaks around 3 pm and 9 pm. CYP7A1 expression is induced by diurnal regulated D-site binding protein (DBP) (89) (90) (91) (92) and Rev-erbα (93), but repressed by the clock genes, DEC2, and E4BP4 (93, 94). These authors conclude that the circadian rhythm of Cyp7a1 is regulated directly by DBP, DEC2 and Rev-erbα/β. However, in Rev-erbα knockout mice, Cyp7a1 expression is induced and bile acid synthesis is stimulated, but the diurnal rhythm of Cyp7a1 remains (77) . These authors suggest that Rev-erbα does not regulate the diurnal rhythm of CYP7A1 but induces CYP7A1 by inhibiting SHP and E4BP4 expression (77) . In contrast, Rev-erbα does not regulate the circadian rhythm of CYP8B1.
FXR REGULATION OF ENTEROHEPATIC CIRCULATION OF BILE ACIDS
In humans, about 0.2-0.6 g of bile acids are synthesized daily in human liver. The enterohepatic circulation of bile acids is illustrated in FXR plays a key role in control of enterohepatic circulation of bile acids (Fig 3) . The bile acid pool is reduced in Ostα/Ostβ -/-mice (103, 104) . This is a result of increased fibroblast growth factor 15 (FGF15) expression in mouse intestine and reduced Cyp7a1 expression in mouse liver (see below). OST appears to be the major bile acid efflux transporter in the intestine. OSTα/OSTβ also has been localized in the sinusoid membrane of hepatocytes (103 
MECHANISMS OF FXR INHIBITION OF CYP7A1
Bile acid synthesis is feedback inhibited by bile acids returning to the liver via enterohepatic circulation to inhibit CYP7A1 (110) . Currently there are two FXRdependent mechanisms for bile acid inhibition of CYP7A1 gene transcription (Fig 3) . In the liver FXR induces SHP to inhibit CYP7A1. In the intestine FXR induces FGF19 to activate liver FGF receptor 4 (FGFR4) signaling to inhibit CYP7A1.
The FXR/SHP pathway
The FXR binding site is not present in the CYP7A1 promoter (67). Three These investigators proposed that FGF15 might function as an enterohepatic signaling to regulate bile acid synthesis (Fig 3) . Furthermore, GW4064 represses Cyp7a1 in liverspecific Fxr knockout mice, but not in intestine specific Fxr knockout mice unequivocally confirming that the intestinal FXR, but not liver FXR is required for bile acid inhibition of Cyp7a1 gene expression (128) . These data also suggest that CYP8B1 is preferentially regulated by the liver FXR/SHP pathway, and not by the FXR/FGF19/FGFR4 pathway. It appears that FGF19 is the bile acid induced "intestinal factor" that is secreted in the ileum to inhibit bile acid synthesis in hepatocytes as proposed by Pandak et al in 1995 (129) .
FGF19 activation of FGFR4 signaling requires β-Klotho, a membrane-bound glycosidase co-expressed with FGFR4 in hepatocytes (Fig 3) . Genetic ablation of the β- pathway is the physiological mechanism for bile acid feedback regulation of bile acid synthesis.
THE AUTOCRINE FUNCTIONS OF FGF19
FGF15 has not been identified in mouse sera and livers, and bile acids do not induce FGF15 expression in mouse liver. Song et al (53) reports recently that bile acids are able to induce FGF19 in primary human hepatocytes. This study shows that CDCA and GW4064 rapidly induce FGF19 mRNA expression, FGF19 protein secretion, and tyrosine phosphorylation of FGFR4, but inhibit CYP7A1 mRNA expression in primary human hepatocytes suggesting that liver produced FGF19 is secreted from hepatocytes to activate FGFR4 signaling in hepatocytes by an autocrine or paracrine mechanism. not be required in FGF19 signaling (53) . It is also noted that induction of FGF19 is sustained for at least 24 hours but induction of SHP mRNA by CDCA and GW4064 is transient reaching the maximum in 1 to 3 hours and reducing to the basal levels after 6 hours of treatment (53) . All these data show a lack of correlation between SHP and CYP7A1 expression levels in FGF19 signaling, in contrast to the inverse relationship between SHP and CYP7A1 expression levels that supports the FXR/SHP pathway. The study by Song et al (53) demonstrates that FGF19/FGFR4 signaling activates and phosphorylates mainly the MAPK/ERK1/2 signaling pathway in human primary hepatocytes (Fig 3) . However, the down stream factor(s) of the FGF19 pathway that inhibits CYP7A1 gene transcription remain unknown.
Schaap et al. (134) reports a study of FGF19 expression in patients with
extrahepatic cholestasis. These investigators observed a 6 and 8-fold higher plasma FGF19 in cholestatic patients than non-cholestatic patients and post-cholestatic patients receiving a biliary stent to drain bile acids, respectively. FGF19 mRNA could be detected in the majority of liver specimens with a wide range of expression levels, and was 31 to 374-fold higher in the cholestatic group than in the drained and non-cholestatic group, respectively. CYP7A1 mRNA expression levels were 37 and 9.8 fold lower in the cholestatic group than in the control and drained groups, respectively. These investigators reasoned that FGF19 should be decreased in extrahepatic cholestasis patients, if FGF19 is only produced in the intestine. They suggest that bile acids accumulated in cholestatic liver could induce FGF19 expression as an adaptive response to cholestatic liver injury.
FXR-INDEPENDENT BILE ACID INHIBITION OF CYP7A1
There are several FXR-independent mechanisms for bile acid inhibition of CYP7A1 (Fig 4) . The secondary bile acid, LCA is a ligand of PXR and VDR. These two receptors bind to the BARE-I sequence in the human CYP7A1 promoter and inhibit CYP7A1 promoter activity (135, 136) . PXR interacts with HNF4α and blocks HNF4α Bile acids also activate epidermal growth factor receptor and the Raf-1/MEK/ERK signaling pathway to inhibit CYP7A1 transcription (29) . Bile acids enhance the insulin receptor signaling in rat primary hepatocytes (34) . Insulin signaling phosphorylates and activates the insulin receptor leading to activation of insulin receptor substrates, PI3K and AKT, which phosphorylates FoxO1 and inhibits CYP7A1 transcription (50) . Bile acidactivated protein kinase C phosphorylates cJun to inhibit CYP7A1 transcription (26) .
During acute phase response to liver injury and regeneration, hepatocyte growth factor (HGF) released from HSC cells activates the HGF receptor cMet and MAPK pathways to inhibit CYP7A1 transcription and bile acid synthesis (52) . All these cell-signaling pathways may play critical roles in protection against bile acid toxicity during liver injury and cholestasis. All these signaling pathways may converge to regulate CYP7A1 chromatin structure by epigenetic mechanism.
CONCLUSION AND FUTURE PERSPECTIVES
Bile acid research in last two decades has contributed significantly to our understanding of the mechanisms of bile acid synthesis and pathogenesis of liver diseases and metabolic syndrome. The CYP7A1 mRNA expression has become a biomarker for studying lipid metabolism in animal models of fatty liver disease, diabetes, obesity, and cholestasis. The mechanism underlying FXR/FGF19/FGFR4 signaling in inhibition of CYP7A1 transcription and bile acid synthesis remains to be elucidated. The genetically modified mouse models are widely used for studying bile acid synthesis and regulation.
However, distinct species-differences in bile acid composition, synthesis and regulation between humans and mice exist. It is imperative that a suitable human model system be developed to verify results from animal studies.
Bile acids and bile acid-activated receptors FXR, PXR, CAR and VDR are therapeutic targets for development of drugs for treatment of gallstone, fatty liver disease, cholestatic liver disease, obesity, diabetes and metabolic syndrome (12, 149, 150) . A bile acid derivative, 6α-ethyl-CDCA has a protective effect on cholestasis (151) 
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